Amolyt Pharma Announces Abstracts Accepted for Presentation at ECE and ENDO

05 May 2023
www.globenewswire.com
Phase 2Phase 3
Amolyt Pharma Announces Abstracts Accepted for Presentation at ECE and ENDO
LYON, France and CAMBRIDGE, Mass., May 05, 2023 (GLOBE NEWSWIRE) -- Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and related diseases, today announced that the company has had multiple abstracts accepted for presentation at the 25th European Congress of Endocrinology (ECE), which is being held May 13-16 in Istanbul, Turkey, and at the 2023 Endocrine Society Meeting (ENDO), which is being held June 15-18 in Chicago, Illinois. These presentations cover both of Amolyt’s development programs, eneboparatide entering Phase 3 for hypoparathyroidism and AZP-3813 entering Phase 1 for acromegaly.
Details of the presentations are as follows:
25th European Congress of Endocrinology (ECE) – May 13-16, Istanbul, Turkey
Title: Eneboparatide, a Novel PTH-1 Receptor AgonistPTH-1 Receptor Agonist, Has No Impact on Bone Parameters Following Chronic Treatment of Non-Human Primates
Format: Oral Presentation
Session: Oral Communications 8: Calcium and Bone
Date: Monday, May 15, 2023
Time: 2:00-3:00 p.m. CEST
Title: Eneboparatide, a Novel PTH-1 Receptor AgonistPTH-1 Receptor Agonist, Induces Rapid Reduction and Normalization of Urinary Calcium in Chronic Hypoparathyroid Patients
Format: Poster / Rapid Oral Presentation
Session: Rapid Communications 8: Calcium and Bone
Date: Monday, May 15, 2023
Time: 3:05-3:40 p.m. CEST
Poster Display: 9:40 a.m. CEST on Sunday, May 14 – 3:30 p.m. CEST on Tuesday, May 16
Title: Treatment of Chronic Hypoparathyroidism by Eneboparatide, a Novel PTH Receptor-1 AgonistPTH Receptor-1 Agonist: Results from a Phase 2a Study
Format: Poster / Rapid Oral Presentation
Session: Rapid Communications 8: Calcium and Bone
Date: Monday, May 15, 2023
Time: 3:05-3:40 p.m. CEST
Poster Display: 9:40 a.m. CEST on Sunday, May 14 – 3:30 p.m. CEST on Tuesday, May 16
Title: AZP-3813, a Bicyclic, 16-Amino Acid Peptide Antagonist of the Human Growth Hormone Receptor, Effectively Suppresses IGF1 in Beagle Dogs
Format: Poster / Rapid Oral Presentation
Session: Rapid Communication 7: Pituitary and Neuroendocrinology 2
Date: Monday, May 15, 2023
Time: 3:05-3:40 p.m. CEST
Poster Display: 9:40 a.m. CEST on Sunday, May 14 – 3:30 p.m. CEST on Tuesday, May 16
2023 Endocrine Society Meeting (ENDO) – June 15-18, Chicago, Illinois
Title: Repeated Treatment with AZP-3813, a Bicyclic, 16-Amino Acid Peptide Antagonist of the Human Growth Hormone Receptor, Induces Enhanced Suppression of IGF1 in Beagle Dogs
Format: Poster Presentation
Session: Neuroendocrinology: Neuroendocrinology and Pituitary: Growth Hormone and Acromegaly - Basic and Translational
Date: Thursday, June 15, 2023
Time: 12:30-1:30 p.m. CST
Poster Display: 9:00 a.m. – 3:00 p.m. CST on Thursday, June 15
Title: Treatment of Chronic Hypoparathyroidism with Eneboparatide (AZP-3601), a Novel PTH 1 Receptor AgonistPTH 1 Receptor Agonist: Results from a Phase 2 Trial
Format: Oral Presentation
Session: Bone 2 - PTH-Relevant Biology, Pathophysiology, and Therapeutics
Date: Saturday, June 17, 2023
Time: 9:45-11:15 a.m. CST
Title: Variations in Clinical Practice Patterns for Hypoparathyroidism
Format: Poster Presentation
Session: Bone and Mineral Metabolism: Hypoparathyroidism
Date: Saturday, June 17, 2023
Time: 1:00-2:00 p.m. CST
Poster Display: 9:00 a.m. – 3:00 p.m. CST on Saturday, June 17
Title: AZP-3601, a Novel PTH 1 Receptor AgonistPTH 1 Receptor Agonist, Induces Rapid Reduction and Normalization of Urinary Calcium in Chronic Hypoparathyroid Patients
Format: Poster Presentation
Session: Bone and Mineral Metabolism: Hypoparathyroidism
Date: Saturday, June 17, 2023
Time: 1:00-2:00 p.m. CST
Poster Display: 9:00 a.m. – 3:00 p.m. CST on Saturday, June 17
Amolyt Pharma, a clinical stage biotechnology company, is building on its team’s established expertise to deliver life-changing treatments to patients suffering from rare endocrine and related diseases. Its development portfolio includes eneboparatide (AZP-3601), a long-acting PTH1 receptor agonist as a potential treatment for hypoparathyroidism, and AZP-3813, a peptide growth hormone receptor antagonist for the potential treatment of acromegaly. Amolyt Pharma aims to further expand and develop its portfolio by leveraging its global network in the field of endocrinology and with support from a strong syndicate of international investors. To learn more, visit https://amolytpharma.com/ or follow us on Twitter and LinkedIn.
Media Inquiries:
Jordyn Temperato
LifeSci Communications
jtemperato@lifescicomms.com
Investors Inquiries:
Ashley Robinson
arr@lifesciadvisors.com
+1.617.430.7577


For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.